SCHEMBL2270244

SCHEMBL2270244

COC(=O)c1ccc(OC2CCCCC2)cc1NC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.58
KDM4E B2RXH2 9/20 0.53
HSD17B10 Q99714 4/20 0.53
MAPK1 P28482 1/20 0.53
TSHR P16473 3/20 0.47
PDE4D Q08499 3/20 0.47
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
ALDH1A1 P00352 6/20 0.46
HPGD P15428 4/20 0.46
POLB P06746 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ELANE P08246 1/20 0.46
PRTN3 P24158 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270108 0.90 MEN1 (0.52) PDE5APDE4DPDE4APDE4BPDE4C
SCHEMBL8041155 0.83 PDE5A (0.66) PDE5AKDM4EHSD17B10TSHRPDE4D
SCHEMBL2269238 0.81 KDM4E (0.68) KDM4EHSD17B10MAPK1TSHRALDH1A1
SCHEMBL5376889 0.80 HIF1A (0.51) PDE5AKDM4ECYP1A2CYP2D6CYP2C19
SCHEMBL24379188 0.77 HIF1A (0.48) PDE5AKDM4EGAACYP1A2CYP2D6
SCHEMBL8902162 0.76 CA12 (0.55) PDE5AMAPK1TSHRALDH1A1HPGD
SCHEMBL19472685 0.76 PDE5A (0.60) PDE5AKDM4EHSD17B10TSHRALDH1A1
SCHEMBL2277733 0.75 KDM4E (0.64) KDM4EHSD17B10MAPK1TSHRALDH1A1
SCHEMBL4213753 0.75 EPHX2 (0.47) PDE5AKDM4EALDH1A1HPGDCYP1A2
SCHEMBL2275077 0.75 KDM4E (0.66) KDM4EHSD17B10MAPK1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PDE5A 2707/4885KDM4E 1257/4885HSD17B10 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.